Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 927Lymphoma 112Recurrence 94Neoplasms, Plasma Cell 92Lymphoma, Non-Hodgkin 67Immunoglobulin Light-chain Amyloidosis 60Hematologic Neoplasms 60Neoplasms 54Smoldering Multiple Myeloma 51Leukemia, Myeloid, Acute 51Leukemia 51Myelodysplastic Syndromes 47Leukemia, Lymphocytic, Chronic, B-Cell 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Hodgkin Disease 37Leukemia, Plasma Cell 26Myeloproliferative Disorders 24Monoclonal Gammopathy of Undetermined Significance 23Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Breast Neoplasms 22Amyloidosis 22Primary Myelofibrosis 21Lymphoma, Follicular 21Waldenstrom Macroglobulinemia 20Ovarian Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, B-Cell 17Colorectal Neoplasms 16

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × Plasma cell × 1 year × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡